X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnersip aims to support the scaling of EDIT-301, Editas Medicine’s experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), from approval to commercialization.
Lead Product(s): EDIT-301
Therapeutic Area: Hematology Product Name: EDIT-301
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Editas Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 27, 2023
Details:
Editas Medicine will utilize the space and Azzur’s services to execute pre-clinical and early-phase clinical manufacturing activities for its cell medicines, including EDIT-301 in development for the treatment of sickle cell disease and beta thalassemia and EDIT-201.
Lead Product(s): EDIT-301
Therapeutic Area: Genetic Disease Product Name: EDIT-301
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Editas Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
